Literature DB >> 25797027

Should diffuse bronchiectasis still be considered a CFTR-related disorder?

Anne Bergougnoux1, Victoria Viart1, Julie Miro2, Sébastien Bommart3, Nicolas Molinari4, Marie des Georges5, Mireille Claustres2, Raphaël Chiron6, Magali Taulan-Cadars7.   

Abstract

BACKGROUND: Although several comprehensive studies have evaluated the role of the CFTR gene in idiopathic diffuse bronchiectasis (DB), it remains controversial.
METHODS: We analyzed the whole coding region of the CFTR gene, its flanking regions and the promoter in 47 DB patients and 47 controls. Available information about demographic, spirometric, radiological and microbiological data for the DB patients was collected. Unclassified CFTR variants were in vitro functionally assessed.
RESULTS: CFTR variants were identified in 24 DB patients and in 27 controls. DB variants were reclassified based on the results of in silico predictive analyses, in vitro functional assays and data from epidemiological and literature databases. Except for the sweat test value, no clear genotype-phenotype correlation was observed.
CONCLUSIONS: DB should not be considered a classical autosomal recessive CFTR-RD. Moreover, although further investigations are necessary, we proposed a new class of "Non-Neutral Variants" whose impact on lung disease requires more studies.
Copyright © 2015 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CFTR gene; Diffuse bronchiectasis; Functional analysis; Variants classification

Mesh:

Substances:

Year:  2015        PMID: 25797027     DOI: 10.1016/j.jcf.2015.02.012

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  9 in total

Review 1.  The therapeutic potential of CFTR modulators for COPD and other airway diseases.

Authors:  George M Solomon; Lianwu Fu; Steven M Rowe; James F Collawn
Journal:  Curr Opin Pharmacol       Date:  2017-11-10       Impact factor: 5.547

2.  Probability of high-risk genetic matching with oocyte and semen donors: complete gene analysis or genotyping test?

Authors:  Marta Molina Romero; Alberto Yoldi Chaure; Miguel Gañán Parra; Purificación Navas Bastida; José Luis Del Pico Sánchez; Ángel Vaquero Argüelles; Paloma de la Fuente Vaquero; Juan Pablo Ramírez López; José Antonio Castilla Alcalá
Journal:  J Assist Reprod Genet       Date:  2022-01-29       Impact factor: 3.412

Review 3.  Pathophysiology and Genetics of Bronchiectasis Unrelated to Cystic Fibrosis.

Authors:  Aleksandra Nikolic
Journal:  Lung       Date:  2018-05-12       Impact factor: 2.584

4.  In Defense of Lady Windermere Syndrome.

Authors:  Jerome M Reich
Journal:  Lung       Date:  2018-05-15       Impact factor: 2.584

5.  Screening for Regulatory Variants in 460 kb Encompassing the CFTR Locus in Cystic Fibrosis Patients.

Authors:  Jenny L Kerschner; Sujana Ghosh; Alekh Paranjapye; Wilmel R Cosme; Marie-Pierre Audrézet; Miyuki Nakakuki; Hiroshi Ishiguro; Claude Férec; Johanna Rommens; Ann Harris
Journal:  J Mol Diagn       Date:  2018-10-05       Impact factor: 5.568

6.  Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics.

Authors:  Lisa J Strug; Tanja Gonska; Gengming He; Katherine Keenan; Wan Ip; Pierre-Yves Boëlle; Fan Lin; Naim Panjwani; Jiafen Gong; Weili Li; David Soave; Bowei Xiao; Elizabeth Tullis; Harvey Rabin; Michael D Parkins; April Price; Peter C Zuberbuhler; Harriet Corvol; Felix Ratjen; Lei Sun; Christine E Bear; Johanna M Rommens
Journal:  Hum Mol Genet       Date:  2016-10-15       Impact factor: 6.150

Review 7.  Role of the SLC26A9 Chloride Channel as Disease Modifier and Potential Therapeutic Target in Cystic Fibrosis.

Authors:  Anita Balázs; Marcus A Mall
Journal:  Front Pharmacol       Date:  2018-10-01       Impact factor: 5.810

8.  The Effect of Synonymous Single-Nucleotide Polymorphisms on an Atypical Cystic Fibrosis Clinical Presentation.

Authors:  Giovana B Bampi; Anabela S Ramalho; Leonardo A Santos; Johannes Wagner; Lieven Dupont; Harry Cuppens; Kris De Boeck; Zoya Ignatova
Journal:  Life (Basel)       Date:  2020-12-27

Review 9.  CFTR targeted therapies: recent advances in cystic fibrosis and possibilities in other diseases of the airways.

Authors:  Sheylan D Patel; Taylor R Bono; Steven M Rowe; George M Solomon
Journal:  Eur Respir Rev       Date:  2020-06-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.